Research Analysts Offer Predictions for argenex Q2 Earnings

argenex SE (NASDAQ:ARGX) – Equities research analysts at Wedbush reduced their Q2 2026 earnings per share (EPS) estimates for argenex in a report issued on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $6.18 per share for the quarter, down from their previous forecast of $6.23. Wedbush has a “Outperform” rating and a $880.00 price objective on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex’s Q3 2026 earnings at $6.73 EPS and FY2026 earnings at $25.75 EPS.

ARGX has been the subject of several other reports. HC Wainwright upped their price target on argenex from $720.00 to $774.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Guggenheim restated a “buy” rating and set a $1,070.00 price target on shares of argenex in a research note on Thursday, September 18th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Wells Fargo & Company upped their target price on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Finally, Piper Sandler upped their target price on argenex from $750.00 to $820.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, argenex currently has a consensus rating of “Buy” and a consensus target price of $817.53.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $812.95 on Tuesday. The firm has a market capitalization of $49.75 billion, a PE ratio of 41.69, a P/E/G ratio of 0.86 and a beta of 0.46. The business has a 50-day moving average of $724.90 and a two-hundred day moving average of $630.74. argenex has a 12 month low of $510.05 and a 12 month high of $813.37.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ARGX. Rakuten Securities Inc. boosted its holdings in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after purchasing an additional 22 shares during the last quarter. WPG Advisers LLC purchased a new position in argenex in the first quarter valued at about $37,000. Golden State Wealth Management LLC purchased a new position in argenex in the first quarter valued at about $44,000. Brooklyn Investment Group boosted its holdings in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares during the last quarter. Finally, MAI Capital Management boosted its holdings in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after purchasing an additional 78 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.